Zobrazeno 1 - 10
of 3 065
pro vyhledávání: '"DiBonaventura M"'
Autor:
Mohty M; Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRS 938, Paris, France., Bahlis NJ; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada., Nooka AK; Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA., DiBonaventura M; Pfizer Inc, New York, New York, USA., Ren J; Pfizer Inc, Collegeville, Pennsylvania, USA., Conte U; Pfizer Inc, New York, New York, USA.
Publikováno v:
British journal of haematology [Br J Haematol] 2024 May; Vol. 204 (5), pp. 1801-1810. Date of Electronic Publication: 2024 Feb 29.
Autor:
Sinyavskaya L; STATLOG Inc, Montreal, Canada., Meche A; Real World Evidence Center of Excellence, Pfizer Inc, New York, NY, USA., Faucher A; STATLOG Inc, Montreal, Canada., Hlavacek P; Value and Evidence, Pfizer Inc, New York, NY, USA., Johnson SMA; STATLOG Inc, Montreal, Canada., DiBonaventura M; Value and Evidence, Pfizer Inc, New York, NY, USA., Vekeman F; STATLOG Inc, Montreal, Canada., Ren J; Statistical Research and Data Science Center, Pfizer Inc, Collegeville, PA, USA., Schepart A; US Medical Affairs, Pfizer Inc, New York, NY, USA.
Publikováno v:
Current medical research and opinion [Curr Med Res Opin] 2024 May; Vol. 40 (5), pp. 789-801. Date of Electronic Publication: 2024 Apr 12.
Autor:
Yu SY, Fan BF, Yang F, DiBonaventura M, Chen YX, Li RY, King-Concialdi K, Kudel I, Hlavacek P, Hopps M, Udall M, Sadosky A, Cappelleri JC
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol Volume 11, Pp 539-550 (2019)
Sheng-Yuan Yu,1 Bi-Fa Fan,2 Fei Yang,1 Marco DiBonaventura,3 Yu-Xuan Chen,4 Ruo-Yu Li,5 Kristen King-Concialdi,6 Ian Kudel,6 Patrick Hlavacek,3 Markay Hopps,3 Margarita Udall,3 Alesia Sadosky,3 Joseph C Cappelleri7 1Department of Neurology, Chinese P
Externí odkaz:
https://doaj.org/article/cfe5a912e42f46e689ac1afecfbb7980
Publikováno v:
Clinical and Experimental Gastroenterology, Vol Volume 12, Pp 263-278 (2019)
Marco Boeri,1 Kelley Myers,2 Claire Ervin,2 Amy Marren,3 Marco DiBonaventura,4 Joseph C Cappelleri,5 Brett Hauber,2 David T Rubin61RTI Health Solutions, Health Preference Assessment, Belfast, BT2 8LA, UK; 2RTI Health Solutions, Health Preference Asse
Externí odkaz:
https://doaj.org/article/d50cbec3c6bf4ff49fb007f4ace2d968
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol Volume 10, Pp 457-475 (2018)
Marco DiBonaventura,1 Antonio Nicolucci,2 Henrik Meincke,3 Agathe Le Lay,3 Janine Fournier4 1Kantar Health, Health Outcomes Practice, New York, NY, USA; 2Center for Outcomes Research and Clinical Epidemiology, Pescara, Italy; 3Novo Nordisk A/S, Soebo
Externí odkaz:
https://doaj.org/article/bf59e1abc20e4062a261282356f399f8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
International Journal of COPD, Vol Volume 12, Pp 529-539 (2017)
Bo Ding,1 Marco DiBonaventura,2 Niklas Karlsson,1 Gina Bergström,1 Ulf Holmgren1 1AstraZeneca Gothenburg, Mölndal, Sweden; 2Kantar Health, New York, NY, USA Introduction: Past research has suggested significant relationships between symptoms and he
Externí odkaz:
https://doaj.org/article/44bed450e2e7492fae3af0d2bd6ac5c1
Publikováno v:
Journal of Pain Research, Vol Volume 9, Pp 967-978 (2016)
Lulu K Lee,1 Nozomi Ebata,2 Patrick Hlavacek,3 Marco DiBonaventura,4 Joseph C Cappelleri,5 Alesia Sadosky3 1Health Outcomes Practice, Kantar Health, Foster City, CA, USA; 2Neuroscience & Pain Medical Affairs, Pfizer Japan Inc., Tokyo, Japan; 3Global
Externí odkaz:
https://doaj.org/article/cfb05aedae2a430c9239fcd6c461dc06
Autor:
Wu JJ; Dermatology Research and Education Foundation, Irvine, CA, USA., Lafeuille MH; Analysis Group, Montreal, QC, Canada., Emond B; Analysis Group, Montreal, QC, Canada., Fakih I; Analysis Group, Montreal, QC, Canada., Duh MS; Analysis Group, Boston, MA, USA., Cappelleri JC; Pfizer Inc., Groton, CT, USA., Yin N; Pfizer Inc., New York, NY, USA., Feeney C; Pfizer Ltd., Surrey, UK., Myers DE; Pfizer Inc., Collegeville, PA, USA., DiBonaventura M; Pfizer Inc., New York, NY, USA. marco.dibonaventura@pfizer.com.
Publikováno v:
Advances in therapy [Adv Ther] 2022 Sep; Vol. 39 (9), pp. 4157-4168. Date of Electronic Publication: 2022 Jul 12.
Publikováno v:
International Journal of COPD, Vol 2016, Iss Issue 1, Pp 1139-1150 (2016)
Bo Ding,1 Marco DiBonaventura,2 Niklas Karlsson,1 Xia Ling31Department of Global Medical Affairs, AstraZeneca, Gothenburg, Sweden; 2Department of Health Outcomes Practice, Kantar Health, New York, NY, USA; 3Department of Medical Affairs China, AstraZ
Externí odkaz:
https://doaj.org/article/8a3e3f5dcd9443e8bab1010e36093015